KRAS and non-small cell lung carcinoma: Mu et al. observed that in stage I NSCLC patients the rate of PD-L1 over-expression was 39.9% (65/163) but there was no significant correlation between PD-L1 expression and EGFR/KRAS/BRAF/ALK expression [51].